Company
Harmony Biosciences Holdings, Inc.
Headquarters: Plymouth Meeting, PA, United States
Employees: 180
CEO: Mr. John Charles Jacobs M.B.A.
Market Cap
$1.84 Billion
USD as of July 1, 2025
Harmony Biosciences Holdings, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Financials
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | $744.9 M |
| EBITDA | $237.9 M |
| Gross Profit TTM | $583.5 M |
| Profit Margin | 20.50% |
| Operating Margin | 30.45% |
| Quarterly Revenue Growth | 19.50% |
Stocks & Indices
Harmony Biosciences Holdings, Inc. has the following listings and related stock indices.
Stock: NASDAQ: HRMY wb_incandescent